ArticleBMC cardiovascular disorders2025
Resveratrol suppresses susceptibility of ventricular arrhythmia in heart failure model.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThis study investigated the efficacy of resveratrol in reducing ventricular arrhythmia (VA) and modulating calcium handling in a heart failure (HF) model.
methodsHF rabbits were established five weeks after coronary artery ligation. The groups included control, HF rabbits, and HF rabbits treated with intraperitoneal injections of resveratrol 2.5 mg/kg (HF + Res group) in the last week. The electrophysiology of the left ventricle (LV) was investigated using epicardial optical mapping. The action potential duration (APD), calcium transient duration (CaiTD), level of fibrosis and apoptosis, and protein and mRNA levels of ion channels and calcium-handling proteins were also measured.
resultsThe HF group demonstrated a reduction in LV ejection fraction, an augmentation in APD80 and CaiTD80, and an escalation in VA inducibility. The administration of resveratrol resulted in the restoration of cardiac function, a reduction in APD80 and CaiTD80, and a decrease in VA, phase singularities, and dominant frequency. In HF, the expression of ion channels such as Cav1.2, RyR, Nav1.5, Kv1.4, Kv1.5, and Kir2.1 was significantly decreased. The level of SERCA2a, a calcium pump essential for intracellular calcium regulation, was also reduced. Treatment with resveratrol effectively restored the expression of these proteins. Concurrently, HF-induced elevations in fibrosis (collagen I), apoptosis (caspase-3), and inflammation (NF-κB) were significantly attenuated by resveratrol. Proteomic profiling further revealed differential regulation of ion channel–associated proteins and enrichment of cardioprotective signaling pathways, underscoring the therapeutic potential of resveratrol in HF.
conclusionsResveratrol ameliorates calcium handling, reverses structural and electrical remodeling, and suppresses VA in a rabbit HF model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.